FGF19 and esophageal adenocarcinoma: Of note, amplifications in the 11q13 chromosome (including FGF3, FGF4, and FGF19), which was found to be negatively correlated with MSI-H in this study, was reported to be potentially associated with hyperprogression upon immune checkpoint inhibitors as observed in three out of four patients with lung cancer or esophageal adenocarcinoma 18.